Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Aboulghar, M. A.
Right arrow Articles by Shaarawy, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aboulghar, M. A.
Right arrow Articles by Shaarawy, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
S. R. Soares, R. Gomez, C. Simon, J. A. Garcia-Velasco, and A. Pellicer
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome
Hum. Reprod. Update, April 2, 2008; (2008) dmn008v1.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. Gomez, M. Gonzalez-Izquierdo, R. C. Zimmermann, E. Novella-Maestre, I. Alonso-Muriel, J. Sanchez-Criado, J. Remohi, C. Simon, and A. Pellicer
Low-Dose Dopamine Agonist Administration Blocks Vascular Endothelial Growth Factor (VEGF)-Mediated Vascular Hyperpermeability without Altering VEGF Receptor 2-Dependent Luteal Angiogenesis in a Rat Ovarian Hyperstimulation Model
Endocrinology, November 1, 2006; 147(11): 5400 - 5411.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T.A. Molskness, R.L. Stouffer, K.A. Burry, M.J. Gorrill, D.M. Lee, and P.E. Patton
Circulating levels of free and total vascular endothelial growth factor (VEGF)-A, soluble VEGF receptors-1 and -2, and angiogenin during ovarian stimulation in non-human primates and women
Hum. Reprod., April 1, 2004; 19(4): 822 - 830.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. Koga, Y. Osuga, O. Tsutsumi, M. Momoeda, A. Suenaga, K. Kugu, T. Fujiwara, Y. Takai, T. Yano, and Y. Taketani
Evidence for the Presence of Angiogenin in Human Follicular Fluid and the Up-Regulation of Its Production by Human Chorionic Gonadotropin and Hypoxia
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3352 - 3355.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
B. K. Zebrowski, S. Yano, W. Liu, R. M. Shaheen, D. J. Hicklin, J. B. Putnam Jr., and L. M. Ellis
Vascular Endothelial Growth Factor Levels and Induction of Permeability in Malignant Pleural Effusions
Clin. Cancer Res., November 1, 1999; 5(11): 3364 - 3368.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Ludwig, W. Jelkmann, O. Bauer, and K. Diedrich
Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration
Hum. Reprod., October 1, 1999; 14(10): 2437 - 2441.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.